Effectiveness of high-dose i.v. immunoglobulin therapy for pregnant women with aspirin-heparin-resistant secondary antiphospholipid syndrome.

Yoko MaesawaMasashi DeguchiKenji TanimuraMayumi MorizaneYasuhiko EbinaHideto Yamada

Published in: Reproductive medicine and biology (2018)

The HIVIg therapy might be beneficial as an immune modifier for pregnant women with AHRAPS. However, the precise indication of which women with AHRAPS who should receive HIVIg therapy remains unknown.

Keyphrases

pregnant women
high dose
low dose
randomized controlled trial
systematic review
cardiovascular events
type diabetes
stem cell transplantation
antiplatelet therapy
acute coronary syndrome
mesenchymal stem cells
atrial fibrillation
smoking cessation